246 related articles for article (PubMed ID: 30506139)
1. Dacomitinib: First Global Approval.
Shirley M
Drugs; 2018 Dec; 78(18):1947-1953. PubMed ID: 30506139
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
[TBL] [Abstract][Full Text] [Related]
4. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jänne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L
Ann Oncol; 2016 Mar; 27(3):423-9. PubMed ID: 26768165
[TBL] [Abstract][Full Text] [Related]
5. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
6. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Lau SCM; Batra U; Mok TSK; Loong HH
Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
[TBL] [Abstract][Full Text] [Related]
7. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
Lavacchi D; Mazzoni F; Giaccone G
Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
[TBL] [Abstract][Full Text] [Related]
8. Dacomitinib in non-small-cell lung cancer: a comprehensive review for clinical application.
Sun H; Wu YL
Future Oncol; 2019 Aug; 15(23):2769-2777. PubMed ID: 31401844
[TBL] [Abstract][Full Text] [Related]
9. Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer.
Santarpia M; Menis J; Chaib I; Gonzalez Cao M; Rosell R
Expert Rev Clin Pharmacol; 2019 Sep; 12(9):831-840. PubMed ID: 31356117
[No Abstract] [Full Text] [Related]
10. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Chawla A; Rosell R; Corral J; Migliorino MR; Pluzanski A; Noonan K; Tang Y; Pastel M; Wilner KD; Wu YL
Drugs; 2021 Feb; 81(2):257-266. PubMed ID: 33331989
[TBL] [Abstract][Full Text] [Related]
11. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
[TBL] [Abstract][Full Text] [Related]
12. Effects of dose modifications on the safety and efficacy of dacomitinib for
Corral J; Mok TS; Nakagawa K; Rosell R; Lee KH; Migliorino MR; Pluzanski A; Linke R; Devgan G; Tan W; Quinn S; Wang T; Wu YL
Future Oncol; 2019 Aug; 15(24):2795-2805. PubMed ID: 31313942
[No Abstract] [Full Text] [Related]
13. Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study).
Zhang B; Shi C; Gao Z; Zhong H; Xiong L; Gu A; Wang W; Chu T; Zhang W; Wang H; Zhang X; Zhong R; Han B
BMC Cancer; 2022 Mar; 22(1):294. PubMed ID: 35305596
[TBL] [Abstract][Full Text] [Related]
14. Mobocertinib: First Approval.
Markham A
Drugs; 2021 Nov; 81(17):2069-2074. PubMed ID: 34716908
[TBL] [Abstract][Full Text] [Related]
15. Dramatic Response of Brain Metastasis from EGFR-mutation-positive NSCLC to Dacomitinib.
Kudo K; Kawakado K; Kawajiri T; Nishi T; Makimoto G; Tamura T; Kuyama S; Tanimoto M
Intern Med; 2020 Jul; 59(14):1739-1740. PubMed ID: 32296006
[TBL] [Abstract][Full Text] [Related]
16. Afatinib: first global approval.
Dungo RT; Keating GM
Drugs; 2013 Sep; 73(13):1503-15. PubMed ID: 23982599
[TBL] [Abstract][Full Text] [Related]
17. Dacomitinib as a retreatment for advanced non-small cell lung cancer patient with an uncommon EGFR mutation.
Morita A; Hosokawa S; Yamada K; Umeno T; Kano H; Kayatani H; Shiojiri M; Sakugawa M; Bessho A
Thorac Cancer; 2021 Apr; 12(8):1248-1251. PubMed ID: 33651475
[TBL] [Abstract][Full Text] [Related]
18. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck.
Kim HS; Kwon HJ; Jung I; Yun MR; Ahn MJ; Kang BW; Sun JM; Kim SB; Yoon DH; Park KU; Lee SH; Koh YW; Kim SH; Choi EC; Koo DH; Sohn JH; Kim B; Kwon NJ; Yun HJ; Lee MG; Lee JH; Kim TM; Kim HR; Kim JH; Paik S; Cho BC
Clin Cancer Res; 2015 Feb; 21(3):544-52. PubMed ID: 25424851
[TBL] [Abstract][Full Text] [Related]
19. Dacomitinib induces objective responses in metastatic brain lesions of patients with EGFR-mutant non-small-cell lung cancer: A brief report.
Peng W; Pu X; Jiang M; Wang J; Li J; Li K; Xu Y; Xu F; Chen B; Wang Q; Cao J; Chen Y; Wu L
Lung Cancer; 2021 Feb; 152():66-70. PubMed ID: 33352385
[TBL] [Abstract][Full Text] [Related]
20. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
